Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system.

[1]  R. Skidgel,et al.  Purification of human urinary prokallikrein. Identification of the site of activation by the metalloproteinase thermolysin. , 1985, The Biochemical journal.

[2]  E. G. Erdös,et al.  Neutral metalloendopeptidase in human lung tissue and cultured cells. , 1985, The American review of respiratory disease.

[3]  J. Schwartz,et al.  High-affinity enkephalin-degrading peptidase in brain is increased after morphine , 1978, Nature.

[4]  R. Skidgel,et al.  Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1 , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  M. Shipp,et al.  Downregulation of enkephalin-mediated inflammatory responses by CDl0/neutral endopeptidase 24.11 , 1990, Nature.

[6]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[7]  M. Kinoshita,et al.  Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. , 1989, American heart journal.

[8]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[9]  T. Moreau,et al.  Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group. , 1991, Biochimica et biophysica acta.

[10]  O. Ratnoff,et al.  Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. , 1961, The Journal of clinical investigation.

[11]  T. Ogihara,et al.  Concentrations and molecular forms of human brain natriuretic peptide in plasma. , 1992, Biochemical and biophysical research communications.

[12]  R. Skidgel,et al.  Neutral endopeptidase 24.11 in human neutrophils: cleavage of chemotactic peptide. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Iwanaga,et al.  Kinetic studies on surface-mediated activation of bovine factor XII and prekallikrein. Effects of kaolin and high-Mr kininogen on the activation reactions. , 1985, European journal of biochemistry.

[14]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[15]  K. Kugiyama,et al.  Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity. , 1996, The Journal of clinical investigation.

[16]  F. España,et al.  The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents. , 1983, The Journal of laboratory and clinical medicine.

[17]  S. Pauwels,et al.  Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat. , 1990, The Biochemical journal.

[18]  K. Nakao,et al.  Human brain natriuretic peptide, a novel cardiac hormone , 1990, The Lancet.

[19]  J. Griffin,et al.  Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[21]  M. Shipp,et al.  CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. , 1991, Blood.

[22]  S. Pauwels,et al.  In vivo metabolism of brain natriuretic peptide in the rat involves endopeptidase 24.11 and angiotensin converting enzyme. , 1990, Biochemical and biophysical research communications.

[23]  I. Iwamoto,et al.  Journal of Leukocyte Biology 49:116-125 (1991) Distribution of Neutral Endopeptidase Activity in Human , 2022 .

[24]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[25]  H. Teraoka,et al.  Stability of brain natriuretic peptide (BNP) in human blood samples. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[26]  S. Iwanaga,et al.  Activation of factor XII and prekallikrein with polysaccharide sulfates and sulfatides: comparison with kaolin-mediated activation. , 1985, Journal of biochemistry.

[27]  K. Wuepper,et al.  A C T I V A T I O N OF H A G E M A N F A C T O R IN SOLID AND F L U I D PHASES* A CRITICAL ROLE OF KALLIKREIN , 2022 .

[28]  H. Wendel,et al.  Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. , 1995, Circulation.